FDA warns Korean drugmaker for repeat violations

The U.S. FDA issued South Korea-based Hanlim Pharm a warning letter over poor aseptic practices and inadequate processes for documentation, among other violations of good manufacturing practice (GMP).
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news